Angiotensin receptor blockers for the treatment of covid-19: pragmatic, adaptive, multicentre, phase 3, randomised controlled trial.

Saved in:
Bibliographic Details
Title: Angiotensin receptor blockers for the treatment of covid-19: pragmatic, adaptive, multicentre, phase 3, randomised controlled trial.
Authors: Jardine MJ; NHMRC Clinical Trials Centre, University of Sydney, Camperdown, NSW, Australia.; Concord Repatriation General Hospital, Concord, NSW, Australia., Kotwal SS; The George Institute for Global Health, University of New South Wales, Newtown, NSW, Australia.; Prince of Wales Hospital, Randwick, NSW, Australia., Bassi A; The George Institute for Global Health, UNSW, New Delhi, India., Hockham C; The George Institute for Global Health, Imperial College London, UK., Jones M; Sydney School of Public Health, University of Sydney, Camperdown, NSW, Australia., Wilcox A; NHMRC Clinical Trials Centre, University of Sydney, Camperdown, NSW, Australia arlen.wilcox@sydney.edu.au., Pollock C; Royal North Shore Hospital, St Leonards, NSW, Australia.; Kolling Institute of Medical Research, University of Sydney, St Leonards, NSW, Australia., Burrell LM; Department of Medicine, University of Melbourne, Austin Health, Heidelberg, VIC, Australia.; Institute of Breathing and Sleep, Heidelberg, VIC, Australia., McGree J; Queensland University of Technology, Brisbane, QLD, Australia., Rathore V; All India Institute of Medical Sciences, Raipur, India., Jenkins CR; Concord Repatriation General Hospital, Concord, NSW, Australia.; The George Institute for Global Health, University of New South Wales, Newtown, NSW, Australia., Gupta L; Maulana Azad Medical College and Lok Nayak Hospital, New Delhi, India., Ritchie A; Concord Repatriation General Hospital, Concord, NSW, Australia., Bangi A; Jivanrekha Multispecialty Hospital, Pune, India., D'Cruz S; Government Medical College and Hospital, Chandigarh, India., McLachlan AJ; Sydney Pharmacy School, The University of Sydney, Camperdown, NSW, Australia., Finfer S; The George Institute for Global Health, University of New South Wales, Newtown, NSW, Australia., Cummins MM; NHMRC Clinical Trials Centre, University of Sydney, Camperdown, NSW, Australia., Snelling T; The Sydney Children's Hospitals Network, Westmead, NSW, Australia., Jha V; The George Institute for Global Health, UNSW, New Delhi, India.; Prasanna School of Public Health, Manipal Academy of Higher Education, Manipal, India.; School of Public Health, Imperial College, London, UK.
Corporate Authors: CLARITY trial investigators
Source: BMJ (Clinical research ed.) [BMJ] 2022 Nov 16; Vol. 379, pp. e072175. Date of Electronic Publication: 2022 Nov 16.
Publication Type: Adaptive Clinical Trial; Clinical Trial, Phase III; Journal Article; Multicenter Study; Pragmatic Clinical Trial; Randomized Controlled Trial
Journal Info: Publisher: British Medical Association Country of Publication: England NLM ID: 8900488 Publication Model: Electronic Cited Medium: Internet ISSN: 1756-1833 (Electronic) Linking ISSN: 09598138 NLM ISO Abbreviation: BMJ Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1756-1833
DOI:10.1136/bmj-2022-072175